Ribo and Madrigal Sign Global Licensing Deal for siRNA MASH Therapies
Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have entered an exclusive global licensing agreement with Madrigal Pharmaceuticals to develop innovative siRNA therapies targeting metabolic dysfunction-associated steatohepatitis (MASH)....

